The immunoproteome and multimorbidity: A Mendelian randomization study - PubMed
an hour ago
- #immunoproteome
- #Mendelian randomization
- #multimorbidity
- The study explores how immune proteins influence multiple diseases to uncover shared mechanisms and therapeutic opportunities.
- Using eight large plasma proteome GWAS, cis-Mendelian randomization was applied to 151 immune proteins and 64 diseases/biomarkers.
- Protein-disease communities were derived from a knowledge graph integrating corrected associations, druggability, indications, and tissue-trait links.
- Immune proteins frequently implicated coronary heart disease, venous thromboembolism, atrial fibrillation, type 2 diabetes, and Parkinson's disease.
- Seven protein communities mapped to pathways like ficolin binding and antimicrobial peptides, showing enrichment for proteins affecting multiple diseases.
- Several associations replicated with colocalization support, including APOE, CD163, and IL-6R across neurodegenerative, cardiometabolic, and inflammatory traits.
- The findings provide genetic support for druggable immune proteins with pleiotropic effects, highlighting opportunities for therapeutic development and indication expansion.